Put companies on watchlist
DocMorris AG
ISIN: CH0042615283
WKN: A0Q6J0
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

DocMorris AG · ISIN: CH0042615283 · EQS - adhoc news (88 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1876919
10 April 2024 07:00AM

DocMorris receives gematik approval for simple digital e-prescription redemption via health card


DocMorris AG / Key word(s): Market Launch
DocMorris AG: DocMorris receives gematik approval for simple digital e-prescription redemption via health card

10-Apr-2024 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Frauenfeld, 10 April 2024

 

Press release
Ad hoc announcement pursuant to Art. 53 LR

 

DocMorris receives gematik approval for simple digital e-prescription redemption via health card

  • Product and provider approval for e-prescription redemption via eHealth-CardLink from DocMorris successfully completed
  • Roll-out of the fully digital redemption channel started in the DocMorris app
  • High user-friendliness with the highest security standards
  • Nationwide, free next-day delivery of prescribed medication
  • New, convenient e-prescription services

DocMorris today successfully completed the process for product and provider approval for the fully digital redemption of e-prescriptions via the electronic health card (eGK = elektronische Gesundheitskarte) and received the corresponding approval from gematik. DocMorris eHealth-CardLink therefore fulfils all the requirements set by gematik as the responsible regulator for eHealth-CardLink solutions. The roll-out of the new e-prescription function in the DocMorris app was started immediately.

“The e-prescription has now largely replaced the traditional pink paper prescription. Around 70 per cent of all prescriptions in Germany are already issued electronically. But until now, there has been no simple, fully digitalised way to redeem prescriptions that works from anywhere. That is now changing. We are the first authorised provider for the eHealth-CardLink solution and are counting on it to win over many patients. The e-prescription is an elementary component of our DocMorris healthcare ecosystem, with which we want to offer everyone the simplest and most reliable healthcare possible,” says Walter Hess, CEO of DocMorris.

The simple redemption process via eGK in the DocMorris app
To use the new solution, the DocMorris app must be installed on the smartphone and logged in. After opening the app, one selects the “Redeem e-prescription” function. The process is recorded via text message and identified by entering the access number (CAN) printed on the eGK. The eGK with the chip is then held to the back of the NFC-enabled (Near Field Communication) smartphone and the medication data is transmitted. The patient can then view their e-prescription and the prescribed medication and, if required, select additional healthcare products to add them to the shopping basket. The process is simple and only takes a few seconds. It is not necessary to enter an eGK PIN.

Highest safety standards
With the official approval, gematik confirms the suitability of DocMorris' eHealth-CardLink in terms of security and data protection. The security requirements defined in agreement with the Federal Office for Information Security (BSI) and the Federal Commissioner for Data Protection and Freedom of Information (BfDI) have been implemented and their effectiveness confirmed by independent experts. In particular, the authenticity and validity of the health card used are checked before each retrieval of e-prescriptions. For this purpose, cryptographic proof is provided in accordance with BSI specifications. Data transmission between the card and the pharmacy is encrypted in a tap-proof and tamper-proof manner and access to the protected insurance data on the health card is technically impossible. With that, the security features of eHealth-CardLink are significantly more comprehensive than those of the physical eGK solution in local pharmacies.

E-prescription enables convenient services
The e-prescription makes online pharmacies faster and more effective. Anyone who redeems an e-prescription at DocMorris by 8 p.m. will receive their medication the very next day. This applies nationwide, even in regions with a poorer (healthcare) infrastructure or for people with long journeys to the nearest local pharmacy.

The new way of redeeming e-prescriptions also makes it possible to provide even better care for chronically ill patients with long-term medication. They can sign up for a follow-up prescription subscription and thus ensure a seamless supply of important medicines. And last but not least, e-prescriptions also allow doctors to issue and send prescriptions to their patients as part of telemedical care.

Further information can be found at: E-prescription for medication information | DocMorris

 

Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

16 April 2024 Q1/2024 Trading update
2 May 2024 Annual General Meeting, Zurich
20 August 2024 2024 Half-year results (conference call/webcast)
15 October 2024 Q3/2024 Trading update

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, marketplace and professional healthcare with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands, with a capacity of over 27 million parcels per year. In Spain and France, the company operates the leading marketplace for health and personal care products in Southern Europe. With its business model, DocMorris offers its patients, customers and partners a broad range of products and services. In doing so, DocMorris is pursuing its vision of creating a digital health ecosystem for everyone to manage their health in one click. The company was renamed from Zur Rose Group AG to DocMorris AG in May 2023 after the Swiss business was sold to Migros/Medbase. Excluding the Swiss business, about 1,600 employees in Germany, the Netherlands, Spain, France and Switzerland generated an external revenue of CHF 1,038 million serving over 9 million active customers in 2023. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

 



End of Inside Information
Language: English
Company: DocMorris AG
Walzmühlestrasse 49
8500 Frauenfeld
Switzerland
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 1876919

 
End of Announcement EQS News Service

1876919  10-Apr-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1876919&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - DocMorris AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.